


## PHARMACEUTICAL 2021



## Jazz Pharmaceuticals plc Rank 9 of 409







## PHARMACEUTICAL 2021







The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 306% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Other Expenses, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 212%, being 567% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	2,839,568
Cost of Goods Sold	0
Intangible Assets	3,153,354
Liabilities, Current	653,745
Liabilities, Non-Current	0
Other Assets	415,044
Other Compr. Net Income	89,041
Other Expenses	578,153
Other Liabilities	0
Other Net Income	-105,940
Property and Equipment	127,935
Research and Development	586,625
Revenues	2,363,567
Selling, General and Administrative Expense	854,233

Output Variable	Value in 1000 USD
Assets	6,535,901
Liabilities	653,745
Expenses	2,019,011
Stockholders Equity	5,882,156
Net Income	238,616
Comprehensive Net Income	283,136
Economic Capital Ratio	212%